Actnowfordiabetes
14/11/2022
21,400
employees
150
Over 150 countries where the
Group’s medicines are distributed
20％
Over 20% of revenue from
brand-name medicines invested
in R&D each year
€ 4.9 billion
euros in revenue in 2021/2022
including €3.7 billion for brand-name medicines and
€1.2 billion for generic activities
4 therapeutic areas
oncology, neuroscience,
immuno-inflammation,
and cardiometabolism